Synairgen (SNG) ORD GBP 0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Synairgen names Joseph Colliver as CFO
11 October 2023 10:26
(Sharecast News) - Drug discovery firm Synairgen revealed on Wednesday that it had tapped Joseph Colliver to take over as chief financial officer.
-
Synairgen posts positive results for phase 2 trial with SNG001 against Covid-19
4 October 2022 08:00
(Sharecast News) - Synairgen announced positive results for its inhaled antiviral protein treatment interferon beta against Covid-19.
-
Synairgen unveils positive clinical trial data
7 September 2022 07:59
(Sharecast News) - Respiratory drug discovery firm Synairgen has announced positive findings from a clinical trial into its experimental antiviral treatment.
-
Synairgen to collaborate with University of Southampton on observational study
5 September 2022 10:42
(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections...
-
Synairgen falls as patient recruitment halted on Covid-19 trial
17 March 2022 12:32
(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2...
-
Synairgen asked to pause activities on Covid-19 treatment trial
3 March 2022 12:20
(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.
-
Synairgen shares plunge as Covid-19 treatment trial fails
21 February 2022 09:27
(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary...
-
Synairgen secures patients for phase III study of Covid treatment, shares jump
11 November 2021 13:03
(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.
Company announcements Announcements
-
Interim Results
26 September 2024 07:00
Synairgen
-
Appointment of New Chairman and Notice of AGM
18 September 2024 07:00
Synairgen
-
Board Change
5 September 2024 07:00
Synairgen
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.